The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10739 malaria professionals are enjoying the free benefits of MalariaWorld today

Covid-19

NOT Open Access | Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia

July 27, 2020 - 12:13 -- NOT Open Access
Author(s): 
Stremmel C, Kellnar A, Massberg S, Kääb S
Reference: 
J Cardiovasc Pharmacol Ther. 2020 Jul 23:1074248420935740

In recent months, the new coronavirus SARS-CoV-2 has emerged as a worldwide threat with about 4.2 million confirmed cases and almost 300 000 deaths. Its major clinical presentation is characterized by respiratory symptoms ranging from mild cough to serve pneumonia with fever and potentially even death. Until today, there is no known medication to improve clinical symptoms or even prevent or fight the infection.

Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal

July 21, 2020 - 15:23 -- Open Access
Author(s): 
Khuroo MS, Sofi AA, Khuroo M
Reference: 
Int J Antimicrob Agents. 2020 Jul 17:106101

The coronavirus infection (COVID-19) has turned in to a global catastrophe and there is an intense search for effective drug therapy. Of all the potential therapies, chloroquine and hydroxychloroquine have been the focus of tremendous public attention. Both drugs have been used in the treatment and prophylaxis of malaria and long-term use of hydroxychloroquine is the cornerstone in the treatment of several auto-immune disorders.

Insights in chloroquine action: perspectives and implications in Malaria and COVID-19

July 21, 2020 - 12:08 -- Open Access
Author(s): 
Pillat MM, Krüger A, Guimarães LMF, Lameu C, de Souza EE, Wrenger C, Ulrich H
Reference: 
Cytometry A. 2020 Jul 19

Malaria is a threat to human mankind and kills about half a million people every year. On the other hand, COVID‐19 resulted in several hundred thousand deaths since December 2019 and remains without an efficient and safe treatment. The antimalarials chloroquine (CQ) and its analogue, hydroxychloroquine (HCQ), have been tested for COVID‐19 treatment, and several conflicting evidence has been obtained.

HIV, tuberculosis, and malaria: how can the impact of COVID-19 be minimised

July 20, 2020 - 15:17 -- Open Access
Author(s): 
Sands P
Reference: 
Lancet Glob Health. 2020 Jul 13:S2214-109X (20)30317-X

In The   Lancet   Global   Health,   Alexandra   Hogan   and   colleagues1  report  the  findings  of  a  modelling  study  in  which  they  estimate  the  number  of  excess  deaths  from  HIV,  tuberculosis,  and  malaria  that  could  plausibly  occur   as   a   consequence   of   the   COVID-19   pandemic.  

NOT Open Access | Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine; from HIV-1 infection to COVID-19

July 7, 2020 - 14:01 -- NOT Open Access
Author(s): 
Naghipour S, Ghodousi M, Rahsepar S, Elyasi S
Reference: 
Expert Rev Anti Infect Ther. 2020 Jul 7

Chloroquine (CQ) and hydroxychloroquine (HCQ), originally were prescribed for prevention or treatment of malaria, but now successfully are used in several rheumatologic diseases. In addition, in recent decades considering their immunomodulatory effects, high tolerably and low cost, they are evaluated for various viral infections from HIV to COVID-19.

Janus sword actions of chloroquine and hydroxychloroquine against COVID-19

July 7, 2020 - 13:46 -- Open Access
Author(s): 
Chen X, Geiger JD
Reference: 
Cell Signal. 2020 Jul 3:109706

Chloroquine (CQ) and its analogue hydroxychloroquine (HCQ) have been thrust into our everyday vernacular because some believe, based on very limited basic and clinical data, that they might be helpful in preventing and/or lessening the severity of the pandemic coronavirus disease 2019 (COVID-19). However, lacking is a temperance in enthusiasm for their possible use as well as sufficient perspective on their effects and side-effects. CQ and HCQ have well-known properties of being diprotic weak bases that preferentially accumulate in acidic organelles (endolysosomes and Golgi apparatus) and neutralize luminal pH of acidic organelles.

COVID-19: Possible Cause of Induction of Relapse of Plasmodium vivax Infection

July 7, 2020 - 13:11 -- Open Access
Author(s): 
Kishore R, Dhakad S, Arif N, Dar L, Mirdha BR, Aggarwal R, Kabra SK
Reference: 
Indian J Pediatr. 2020 Jul 3:1-2

To the Editor: In ongoing pandemic of novel corona virus disease (COVID-19), clinicians are observing atypical manifestations of the disease.

Malaria and Parasitic Neglected Tropical Diseases: Potential Syndemics with COVID-19

June 3, 2020 - 06:50 -- Open Access
Author(s): 
Gutman JR, Lucchi NW, Cantey PT, Steinhardt LC, Samuels AM, Kamb ML, Kapella BK, McElroy PD, Udhayakumar V, Lindblade KA
Reference: 
Am J Trop Med Hyg. 2020 Jun 1

The COVID-19 pandemic, caused by SARS-CoV-2, have surpassed 5 million cases globally. Current models suggest that low- and middle-income countries (LMICs) will have a similar incidence but substantially lower mortality rate than high-income countries. However, malaria and neglected tropical diseases (NTDs) are prevalent in LMICs, and coinfections are likely.

COVID-19 and the impact on malaria

June 2, 2020 - 09:36 -- Open Access
Author(s): 
Chiodini J
Reference: 
Travel Med Infect Dis. 2020 May 29:101758

As COVID -19 continues to dominate the health and political agendas in so many countries around the world, so does its devastating impact on other diseases become apparent. Malaria is just one of these.

Dose Optimization of Hydroxychloroquine for COVID-19: Do Blood Concentrations Matter

June 2, 2020 - 09:32 -- Open Access
Author(s): 
Ippolito MM, Flexner C
Reference: 
Clin Infect Dis. 2020 May 31:ciaa691

Clinical trials of hydroxychloroquine (HCQ) for the treatment of coronavirus infection-2019 (COVID-19) are moving forward on the heels of conflicting, and sometimes controversial, observational studies out of China and France from the first months of the pandemic.

Pages

Subscribe to RSS - Covid-19